噻托溴铵奥达特罗能倍乐的效果好吗

In patients who had not received maintenance therapy before, lung function was more than doubled compared to Spirax Respimat alone.

In patients who were not on maintenance bronchodilator therapy at baseline, treatment with tiotropium bromide and olodaterol Respimat resulted in more than double the improvement in lung function compared with Slava Respimat alone (148 ml vs 72 ml I) 1 (Abstract 64799). Compared with Slava Respimat, tiotropium olodaterol Respimat was shown to significantly improve lung function in all stages of COPD I; lung function improvements were greatest in the early stages of COPD II2,3. The safety profile of tiotropium, olodaterol and Respimat is comparable to that of Slava Respimat or Striverdi (olodaterol) when used alone.

New analysis shows that tiotropium, olodaterol and Respimat are effective with or without inhaled corticosteroids (ICS). A new in-depth analysis of the TONADO® study shows that almost 40% of patients with less severe COPD (GOLD A/B V) were receiving ICS therapy when the trial began. These data are consistent with previous reports of overuse of ICS-based therapies for early management of COPD. 15,16 The GOLD guidelines only recommend the use of ICS in patients with severely impaired lung function (GOLD C/D) and those with a high risk of exacerbation.

At the time of the trial, regardless of whether patients were using ICS, VI data showed that tiotropium bromide and olodaterol Respimat significantly improved lung function I compared with Slava Respimat (patients using ICS improved by 133 ml (p<0.001 vs. tiotropium bromide 5 ug) and patients not using ICS improved by 149 ml (p<0.001 vs. tiotropium bromide 5 ug).

II Global Initiative for Chronic Obstructive Lung Disease (GOLD) Group 2 patients had greater improvement than patients in Group 3/4 (based on lung function measurements), and patients in GOLD Group A/B had greater improvement than patients in GOLD Group C/D (based on self-reported history of COPD exacerbations and lung function measurements).

Results from the OTIVACTO study, presented at the European Respiratory Society's annual meeting, showed that patients who used the treatment experienced improvements in both their overall health and their ability to carry out daily activities. Studies also show that patients are satisfied with both the inhalation and operation of the Respimat device.

Recommended related hot articles: /newsDetail/83874.html